TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05875090

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Glaucoma Screening
Description: Non-invasive diagnostic techniques will screen subjects in primary care setting for the existence of Glaucoma and categorised them in a binary system: referrable vs non-referrable to a Hospital-based Glaucoma Clinic

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Glaucoma Screening
Description: Non-invasive diagnostic techniques will screen subjects in primary care setting for the existence of Glaucoma and categorised them in a binary system: referrable vs non-referrable to a Hospital-based Glaucoma Clinic
Study: NCT05747781

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pilot Phase: standardized behavioral task
Description: Pilot Phase:~* Mobility under variable light conditions (scotopic, photopic, glare, dark adaptation), performed in a virtual environment.~* Visual search for objects in real life scenes (office, kitchen, living room) performed in a virtual environment.~* Ability to drive (UFOV and DVFAT psychophysical tests).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Validation Phase: standardized behavioral task
Description: Validation Phase:~* Mobility in variable light conditions (photopic and scotopic), performed in real and virtual environments.~* Visual search for objects in real scenes (office, kitchen, bedroom, living room) performed in a virtual environment.~* Driving ability (two psychophysical tests UFOV and DVFAT, one supervised road test).
Study: NCT06178380

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation
Description: For the experimental group:~Isokinetic training Antigravity treadmill Posturography~For the control group:~Patients will receive a standard rehabilitation prescription comprising:~Physiotherapy , muscle stretching and strengthening , proprioceptive exercises, and self-programmed
Study: NCT05392998

Intervention type: DEVICE
Intervention: Cataract surgery with Vivity intraocular lens implantation
Description: Cataract surgery with Vivity intraocular lens implantation
Study: NCT06141486

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MRI contrast-enhancing agents
Description: IV, as per respective label
Study: NCT05655520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: Oral softgel lipid capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: Oral softgel lipid capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: Oral softgel lipid capsules
Study: NCT06082830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention arm includes five components:~1. Personalized goal: Participants will complete an interview with a registered dietitian to review their baseline diet quality data and establish their personalized dietary goals.~2. Meal timing: Participants will receive information on why eating later at night is detrimental and specific strategies on how to limit eating past 8pm in the evening.~3. Nutrition skills: Participants will receive nutrition education and cooking skills text messages, using adolescent specific guidance from the Dietary Guidelines for Americans.~4. Home food environment: Participants will receive text messages on how to better select and prepare foods in the home environment (e.g., fruit and vegetable availability).~5. Engagement strategies: Researchers will design and implement text messages that recognize participant time and effort (e.g., text badges in recognition of completing the first study week).
Study: NCT06413524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body Vibration Therapy
Description: Each session includes six series, each lasting 2 minutes, with a frequency of 35 Hz and an amplitude of 2 mm, with a 60-second rest interval between series. For the starting position, the patient stands relaxed on the platform, holding the WBV platform handles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Local Vibration Therapy
Description: Each session includes six series, each lasting 2 minutes, with a frequency of 35 Hz and an amplitude of 2 mm, with a 60-second rest interval between series. After the warm-up exercise, the researcher helps the patient wear the localized vibration instrument. During the vibration, participants will hold onto the handle to ensure balance stability.
Study: NCT06121297

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CABA-201
Description: Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Study: NCT05841407

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High nitrate isotonic drink
Description: High nitrate (12.9 mmol) drink with carbohydrate and minerals

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: No nitrate isotonic drink
Description: Carbohydrate and mineral isotonic drink
Study: NCT05430555

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR
Description: Single-dose intravenous infusion of MAGE-A1 directed TCR-transgenic T cells following a conditioning chemotherapy
Study: NCT05702229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: an anti PD-1 and anti-TIGIT bispecific antibody; IV infusion
Study: NCT05781347

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stretta
Description: Stretta is a FDA approved device for the management of GERD.
Study: NCT05702229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: an anti PD-1 and anti-TIGIT bispecific antibody; IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: an anti PD-1 and anti CTLA-4 bispecific antibody; IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: an anti PD-1 and anti CTLA-4 bispecific antibody; IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: 5-fluorouracil 400 mg/m\^2 IV, oxaliplatin 85 mg/m\^2, leucovorin 400 mg/m\^2 (or levoleucovorin 200 mg/m\^2 when locally preferred and available), day 1, 5-fluorouracil 1200 mg/m\^2 IV 24 h day 1-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: 5-fluorouracil 400 mg/m\^2 IV, oxaliplatin 85 mg/m\^2, leucovorin 400 mg/m\^2 (or levoleucovorin 200 mg/m\^2 when locally preferred and available), day 1, 5-fluorouracil 1200 mg/m\^2 IV 24 h day 1-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: 5-fluorouracil 400 mg/m\^2 IV, oxaliplatin 85 mg/m\^2, leucovorin 400 mg/m\^2 (or levoleucovorin 200 mg/m\^2 when locally preferred and available), day 1, 5-fluorouracil 1200 mg/m\^2 IV 24 h day 1-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: capecitabine 1000 mg/m\^2 BID, days 1 to 14, oxaliplatin 130 mg/m\^2, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: capecitabine 1000 mg/m\^2 BID, days 1 to 14, oxaliplatin 130 mg/m\^2, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: capecitabine 1000 mg/m\^2 BID, days 1 to 14, oxaliplatin 130 mg/m\^2, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7789
Description: an anti PD 1 and anti TIM 3 bispecific antibody; IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7789
Description: an anti PD 1 and anti TIM 3 bispecific antibody; IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0901
Description: an anti Claudin18.2 ADC; IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0901
Description: an anti Claudin18.2 ADC; IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0901
Description: an anti Claudin18.2 ADC; IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU, IV infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU, IV infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU, IV infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral take, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral take, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral take, Q3W
Study: NCT06450314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinuation of the anti-HER2 maintenance therapy
Description: Heroes is a de-escalation study. Patient must have received continuous anti-HER2 targeted therapy (including Trastuzumab, Trastuzumab/Pertuzumab, Trastuzumab-Deruxtecan, T-DM1) for at least 2 years in any line setting for their HER2-positive metastatic breast cancer with complete response or partial response at last radiological assessment. Patients with ctDNA negative test at baseline will stop their anti-HER2 targeted therapy during the study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring with signatera test
Description: ctDNA test will be performed at 1.5 month after inclusion and every 3 months during 2 years.~Note: For the ctDNA negative patients who become ctDNA positive: ctDNA test will be performed once, 3 months after restarting treatment (+/-1 week).
Study: NCT05771467

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive Ophthalmologic Examination
Description: Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters, optical coherence tomography angiography (OCTA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive Ophthalmologic Examination
Description: Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters, optical coherence tomography angiography (OCTA)
Study: NCT06492213

Intervention type: OTHER
Intervention: No interventions
Description: It is a observational study to investigate the efficacy and safety of PRP combined PRF on IONa compared to PRF alone.

Intervention type: OTHER
Intervention: No interventions
Description: It is a observational study to investigate the efficacy and safety of PRP combined PRF on IONa compared to PRF alone.
Study: NCT04095260

Intervention type: OTHER
Intervention: Pre-season strength and conditioning program
Description: The structured physical performance assessment will include functional movement testing, motor coordination testing, joint mobility screen, muscle strength testing, and agility performance testing. These measures will assess the effectiveness of pre-season strength and conditioning program to reduce musculoskeletal impairments and increase resistance to injury.
Study: NCT06527664

Intervention type: DEVICE
Intervention: custom-made acetabular implant
Description: custom-made acetabular implant produced with additive manufacturing, to fill the bony loss in Paprosky III bone defects
Study: NCT06392308

Intervention type: OTHER
Intervention: none intervention
Description: No interventions are administered to either group of patients.

Intervention type: OTHER
Intervention: none intervention
Description: No interventions are administered to either group of patients.
Study: NCT06379607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow High Flow Nasal Cannula
Description: High Flow Nasal Cannula will be applied in both experimental groups but different flow rates will be used in each arm; this arm will use higher flow rates.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Flow High Flow Nasal Cannula
Description: High Flow Nasal Cannula will be applied in both experimental groups but different flow rates will be used in each arm; this arm will use lower flow rates.
Study: NCT05502107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRESS Intervention
Description: The study intervention is PRESS protocol training and educational delivered to EMS providers, followed by protocol implementation. EMS providers will be trained to screen all EMS patients for protocol eligibility and will start using the protocol at the beginning of the intervention phase. The PRESS EMS protocol includes 2 major components: 1) an evidence-based sepsis screening tool, and 2) a prehospital sepsis alert call to the receiving hospital for participants who screen positive. Upon arrival to the ED, ED providers will provide immediate medical assessment to the patient to determine whether there is concern for sepsis. If the treating provider determines there is concern for sepsis, the provider will deliver usual sepsis care per local hospital protocols, workflows, or care pathways. Sepsis treatment interventions will not be specified by this study protocol.
Study: NCT06582043

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SCARCr tester 1
Description: Twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SCARCr tester 1
Description: Twice daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Twice daily
Study: NCT06178198

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablative radioembolization using Yttrium-90 resin microspheres
Description: Based on 99mTc-MAA mapping, a partition model (multi-compartment MIRD) is employed to plan for a radiation dose of 400 (± 30%) to the tumor. If delivering this dose to the tumor is challenging due to lung dose limitations, the maximum feasible dose is administered to the tumor while maintaining the estimated lung dose below 15 Gy. While treating the entire tumor with a single high-dose radioembolization session is preferred, if necessary due to considerations like estimated lung dose, the treatment can be divided into two sessions, keeping the cumulative lung dose below 25 Gy. For any methods not covered in this discussion, refer to the SIR-Sphere user manual by Sirtex.
Study: NCT04973826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam-Avibactam
Description: 500/167 mg ATM/AVI loading infusion, followed by 1500/500 mg ATM/AVI extended loading infusion, then 1500/500 mg ATM/AVI maintenance dose infusion every 6 hours
Study: NCT06439992

Intervention type: DRUG
Intervention: 18F-Fluselenamyl
Description: Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan of the head and neck.

Intervention type: DRUG
Intervention: 18F-Fluselenamyl
Description: Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan of the head and neck.
Study: NCT06367790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: The athletes included in the experimental group will undergo an intervention using a plyometric exercise protocol, 2 days a week, and dry needling of the gastrocnemius muscles will be applied in a weekly session.~To perform the dry needling intervention, 0.3x50mm disposable steel needles will be used, applying the quick in-and-out technique. To do this, first of all, the intervention area will be cleaned with alcohol and sterile gloves will be used to perform the manoeuvre in complete safety. The active or latent trigger point is then located within the taut band by inserting the needle deeper and deeper, and then moving the needle up and down in search of a local contraction response. A maximum of 8 insertions or up to the athlete's tolerance limit will be applied.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The athletes included in the control group will perform an intervention using a plyometric exercise protocol, 2 days a week, under the same conditions as the experimental group.
Study: NCT05360576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSP-5415 (etonogestrel/ethinyl estradiol vaginal ring)
Description: To prevent pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LSP-5415 (etonogestrel/ethinyl estradiol vaginal ring)
Description: To prevent pregnancy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NuvaRing Vaginal Ring
Description: To prevent pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuvaRing Vaginal Ring
Description: To prevent pregnancy
Study: NCT05877781

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Palmitoylethanolamide
Description: 8-week treatment 3x400 mg per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Palmitoylethanolamide
Description: 8-week treatment 3x400 mg per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Palmitoylethanolamide
Description: 8-week treatment 3x400 mg per day
Study: NCT06381986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHJ002
Description: Topical ophthalmic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical ophthalmic
Study: NCT05877781

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Palmitoylethanolamide
Description: 8-week treatment 3x400 mg per day
Study: NCT05473767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check Up Heart
Description: Family Check-Up Heart consists of the Family Check up with an added heart health component. The Family Check-Up Heart assessment will include evaluations of maternal cardiovascular health; specifically, measurement of maternal blood pressure, body mass index, diet quality, exercise, and smoking, which will be included in the feedback session. After the Feedback Session participants will also receive information about healthy eating and weight loss, stress management, and smoking and to monitor weight and blood pressure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Check-Up
Description: The Family Check-Up typically takes place over the course of 3-5 sessions, each about an hour long. First, a trained Family Check-Up family coach will conduct an Initial Interview. Second is an assessment of that includes questionnaires and videotaped interaction tasks. Third, during the Feedback Session, the family coach discusses with the participant strengths and challenges for their child and family as a whole. They then set goals for their family to support and maintain strengths, and to address any areas of concern. After the Feedback Session families have the option to continue meeting with their family coach to support the child's development and improve parental well-being.
Study: NCT05106712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 4000IU per day for around 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: oral Clomiphene citrate using its respective Stair-step dosage protocol as follow: 50 mg, 100 mg, and 150 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: oral Letrozole using its respective Stair-step dosage protocol as follow: 5 mg, 5 mg, and 7.5 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively, respectively.
Study: NCT04570150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Subjects who are randomized to into the sugammadex arm (Arm I) will receive sugammadex for reversal of neuromuscular block at the completion of their anesthetic; Outcomes measures will be recorded and compared with those from Arm II (neostigmine group).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neostigmine
Description: Subjects who are randomized into the neostigmine arm (Arm II) will receive neostigmine for reversal of neuromuscular block at the completion of their anesthetic; Outcomes measures will be recorded and compared with those from Arm I (sugammadex group).
Study: NCT05106712

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: participants in the control (Placebo) group will be treated with equal amount of placebo tablets per day for the same duration
Study: NCT06318169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegozafermin
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegozafermin
Description: Subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study: NCT03692494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care voice therapy
Description: Exercises will include improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relaxation techniques to the neck and shoulder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care voice therapy
Description: Exercises will include improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relaxation techniques to the neck and shoulder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care voice therapy
Description: Exercises will include improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relaxation techniques to the neck and shoulder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expiratory muscle strength training (EMST)
Description: EMST150 used at 75% of their maximum expiratory pressure. Participants will be directed to perform 5 sets of 5 breaths, 5 days per week, for 5 weeks, at the pressure threshold established in therapy. Maximum expiratory pressure will then be determined at the beginning of each therapy session and recalibration of the device will be performed if indicated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expiratory muscle strength training (EMST)
Description: EMST150 used at 75% of their maximum expiratory pressure. Participants will be directed to perform 5 sets of 5 breaths, 5 days per week, for 5 weeks, at the pressure threshold established in therapy. Maximum expiratory pressure will then be determined at the beginning of each therapy session and recalibration of the device will be performed if indicated.
Study: NCT05604690

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avacc 10
Description: Intranasal application of either low dose or high dose of Covid 19 vaccine.
Study: NCT06391775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN1055
Description: Intravenous (IV) administration.
Study: NCT05604690

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Outer Membrane Vesicles (OMV) : OMV alone in vehicle
Description: OMV will be administered via intranasal route.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via intranasal route.